Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03842761
Other study ID # 1366-0020
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 6, 2019
Est. completion date May 20, 2021

Study information

Verified date June 2021
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this trial is the evaluation of safety and tolerability in patients with mild to moderate hepatic impairment [Child-Turcotte-Pugh (CTP) classification A and B] over different dose regimes of BI 685509 compared to placebo. A secondary objective is to investigate pharmacokinetics of different doses of BI 685509 in patients with mild to moderate hepatic impairment (CTP A and CTP B). In addition, another secondary objective is to compare safety, tolerability, and pharmacokinetics in patients with mild to moderate hepatic impairment (CTP A and CTP B) of single BI 685509 dose to individually matched healthy volunteers


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date May 20, 2021
Est. primary completion date April 9, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria for all trial participants: - Age = 18 years at Screening - Male or female. Women of childbearing potential (WOCBP) participants and male participants able to father a child must be ready and able to use a highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly throughout the Trial - Mean Arterial Pressure (MAP) = 85 mmHg at screening visit - Estimated Glomerular Filtration rate (eGFR) > 70 mL/min/1.73m² according to the CKD-EPI formula at screening visit - Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Key inclusion for Patient Groups 1 and 2 - If on treatment with non-selective beta blockers (NSBB), stable dose since = 8 weeks prior to screening, with no planned dose change of the therapy during study conduct. All other medications stable 4 weeks prior to screening. - Patient Group 1: Patients with CTP A and portal hypertension (defined as liver stiffness >15 kPa during screening) and without a previous decompensation event [ascites, variceal hemorrhage, encephalopathy, or jaundice (except Gilbert's disease or hemolysis when bilirubin will be almost exclusively indirect hyperbilirubinemia)]. Self-limited and resolved historical events of decompensation like ascites or encephalopathy are allowed if they have occurred at least 6 weeks prior to screening and do not require continued therapeutic intervention at the time of screening. - Patient Group 2: Patients with CTP B (with liver stiffness >15 kPa during screening) Key inclusion for Healthy Volunteer group - Subjects who are healthy, according to the investigator's assessment, individually matched to a participant among Patient Groups 1 and 2 according to the following criteria: age within ± 5 years, body weight within ± 15%, and gender - Further inclusion criteria apply Key exclusion for all trial participants - Ongoing chronic alcohol or drug use, which in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial. - History of relevant orthostatic hypotension, fainting spells, or blackouts based on the investigator´s judgment Key exclusion for Patient Groups - Patient Group 2: treatment-refractory ascites - Patient Group 2: recent decompensation event (refractory ascites, recurrent variceal hemorrhage, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis or hepatorenal syndrome) within 6 weeks of screening - Further exclusion criteria apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BI 685509
Tablet
Placebo
Tablet

Locations

Country Name City State
United States American Research Corporation at the Texas Liver Institute San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of subjects with drug-related Adverse Events (AEs) among different dose regimes over each up-titration Up to day 28
Secondary AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to time of the last quantifiable data point) Baseline and Up to 72 hours
Secondary Cmax (maximum measured concentration of the analyte in plasma) Up to 72 hours
Secondary AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) [AUCt,ss will be AUC0-12,ss for bid dosing] Up to 72 hours
Secondary Cmax,ss (maximum measured concentration of the analyte in plasma at steady) Up to 72 hours
Secondary Change from baseline in seated systolic blood pressure (SBP) Baseline and Up to 28 days
Secondary Change from baseline in seated diastolic blood pressure (DBP) Baseline and Up to 28 days
Secondary Change from baseline in heart rate (HR) Baseline and Up to 28 days
Secondary Change from baseline in body weight Baseline and Up to 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links